IC
MCID: INT143
MIFTS: 66

Interstitial Cystitis (IC)

Categories: Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Interstitial Cystitis

MalaCards integrated aliases for Interstitial Cystitis:

Name: Interstitial Cystitis 12 76 53 59 37 43 3 15 73
Painful Bladder Syndrome 53 59 73
Bladder Pain Syndrome 53 59 73
Interstitial Cystitis/painful Bladder Syndrome 53 59
Interstitial Cystitis/bladder Pain Syndrome 53 59
Trigonitis 53 73
Ic/bps 53 59
Ic/pbs 53 59
Ic 53 3
Chronic Interstitial Cystitis 73
Pelvic Congestion Syndrome 73
Cystitis, Interstitial 44
Pelvic Pain Syndrome 53
Ulcerative Cystitis 12
Pelvic Pain 43
Pbs 53

Characteristics:

Orphanet epidemiological data:

59
interstitial cystitis
Prevalence: 1-5/10000 (Finland),1-5/10000 (United States),1-9/1000000 (Finland); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:13949
MeSH 44 D018856
NCIt 50 C27189
Orphanet 59 ORPHA37202
UMLS via Orphanet 74 C1720830 C0282488 C3160917 more
MESH via Orphanet 45 D018856
ICD10 via Orphanet 34 N30.1
KEGG 37 H01551
ICD10 33 N30.1

Summaries for Interstitial Cystitis

NIH Rare Diseases : 53 Interstitial cystitis (IC) is a chronic condition that causes painful urinary symptoms. Symptoms and severity can vary. Some people may have only mild discomfort, or feel tenderness or pressure in the bladder or pelvis. Others may experience intense bladder pain, urgent or frequent needs to urinate, or pain during sexual intercourse. Symptoms may be constant, or they may come and go. Some people with IC have Hunner's ulcers (areas of inflammation on the bladder wall, identified by cytoscopy). The exact cause of IC is not known. While the symptoms are similar to those of a bladder infection, IC is not an infection. It occurs more commonly in women, and in people with other chronic pain disorders such as irritable bowel syndrome or fibromyalgia. There is no cure for IC, but there are treatment options to help relieve the symptoms. No single treatment works for all people with IC. Often, people try different treatments or combinations of treatments before finding something that works. Treatment options may include lifestyle changes, oral or topical medications, bladder instillations, neuromodulation therapy, Botox injections in the bladder muscles, and surgery (in rare cases). Without treatment, IC can affect a person's sleep, daily activities, and social life.

MalaCards based summary : Interstitial Cystitis, also known as painful bladder syndrome, is related to bladder disease and cystitis, and has symptoms including pain and other symptoms associated with female genital organs, mittelschmerz and unspecified symptom associated with female genital organs. An important gene associated with Interstitial Cystitis is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Acetylcholine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and prostate, and related phenotypes are pain and abnormality of the menstrual cycle

MedlinePlus : 43 Interstitial cystitis (IC) is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. It is far more common in women than in men. The symptoms vary from person to person. Some people may have pain without urgency or frequency. Others have urgency and frequency without pain. Women's symptoms often get worse during their periods. They may also have pain with sexual intercourse. The cause of IC isn't known. There is no one test to tell if you have it. Doctors often run tests to rule out other possible causes of symptoms. There is no cure for IC, but treatments can help most people feel better. They include Distending, or inflating, the bladder Bathing the inside of the bladder with a drug solution Oral medicines Electrical nerve stimulation Physical therapy Lifestyle changes Bladder training In rare cases, surgery NIH: National Institute of Diabetes and Digestive and Kidney Diseases

CDC : 3 Interstitial Cystitis (IC) is a chronic bladder condition resulting in recurring discomfort or pain in the bladder or surrounding pelvic region. People with IC usually have inflamed or irritated bladder walls which can cause scarring and stiffening of the bladder.

Wikipedia : 76 Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a type of chronic pain that... more...

Related Diseases for Interstitial Cystitis

Diseases in the Interstitial Cystitis family:

Chronic Interstitial Cystitis

Diseases related to Interstitial Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 506)
# Related Disease Score Top Affiliating Genes
1 bladder disease 31.8 CDH1 HBEGF NGF TRPV1 UPK3A
2 cystitis 31.1 CXCL8 EGF HBEGF IL6 KNG1 NGF
3 migraine with or without aura 1 31.1 P2RX3 TAC1 TRPV1
4 bacteriuria 30.3 CXCL8 IL6 UMOD
5 urinary tract obstruction 30.1 CDH1 EGF HBEGF UMOD
6 adenomyosis 29.9 CDH1 NGF TRPV1
7 chronic cystitis 29.9 NGF UPK3A
8 esophagitis 29.8 CXCL8 IL6 TRPV1
9 somatoform disorder 29.6 NGF TAC1 TRPV1
10 pulpitis 29.6 CXCL8 IL6 KNG1 TRPV1
11 dry eye syndrome 29.5 EGF IL6 NGF TRPV1
12 paine syndrome 29.4 BDNF NGF TAC1 TRPV1
13 lung disease 29.3 ADRB2 CXCL8 CXCR3 IL6
14 pulmonary disease, chronic obstructive 29.3 ADRB2 CXCL8 CXCR3 IL6 TRPV1
15 multiple sclerosis 29.3 BDNF CXCR3 IL6 NGF
16 asthma 28.6 ADRB2 BDNF CXCL8 IL6 KNG1 NGF
17 trigonitis 12.6
18 chronic interstitial cystitis 12.6
19 congenital disorder of glycosylation, type ic 12.5
20 pseudohypoparathyroidism, type ic 12.5
21 cutis laxa, autosomal recessive, type ic 12.3
22 bladder trigone cancer 12.3
23 glycogen storage disease ic 12.3
24 neuropathy, hereditary sensory and autonomic, type ic 12.2
25 usher syndrome, type ic 12.2
26 amelogenesis imperfecta, type ic 12.2
27 lymphedema, hereditary, ic 12.2
28 prune belly syndrome 12.1
29 iridocorneal endothelial syndrome 12.0
30 isolated focal cortical dysplasia type ic 12.0
31 alg6-congenital disorder of glycosylation 11.9
32 urethral syndrome 11.6
33 pain - chronic 11.6
34 plastic bronchitis 11.4
35 charcot-marie-tooth disease, demyelinating, type 1c 11.4
36 myasthenic syndrome, congenital, 5 11.4
37 cogan-reese syndrome 11.3
38 cholera 11.3
39 ichthyosis--cheek--eyebrow syndrome 11.3
40 diarrhea 11.3
41 corneal endothelial dystrophy 11.2
42 convulsions, familial infantile, with paroxysmal choreoathetosis 11.2
43 autosomal dominant limb-girdle muscular dystrophy type 1c 11.2
44 ciliary dyskinesia, primary, 1 11.1
45 essential iris atrophy 11.1
46 polycystic ovary syndrome 11.1
47 ovarian remnant syndrome 11.1
48 chylomicronemia, familial, due to circulating inhibitor of lipoprotein lipase 11.0
49 navicular bone, accessory 11.0
50 congenital disorder of glycosylation, type ib 11.0

Comorbidity relations with Interstitial Cystitis via Phenotypic Disease Network (PDN):


Acute Cystitis Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Interstitial Cystitis:



Diseases related to Interstitial Cystitis

Symptoms & Phenotypes for Interstitial Cystitis

Human phenotypes related to Interstitial Cystitis:

59 32 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0012531
2 abnormality of the menstrual cycle 59 32 hallmark (90%) Very frequent (99-80%) HP:0000140
3 abnormality of the urethra 59 32 hallmark (90%) Very frequent (99-80%) HP:0000795
4 urinary urgency 59 32 hallmark (90%) Very frequent (99-80%) HP:0000012
5 pollakisuria 59 32 hallmark (90%) Very frequent (99-80%) HP:0100515
6 dyspareunia 59 32 hallmark (90%) Very frequent (99-80%) HP:0030016
7 nocturia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000017
8 abnormality of the labia 59 32 hallmark (90%) Very frequent (99-80%) HP:0000058
9 urinary bladder inflammation 59 32 hallmark (90%) Very frequent (99-80%) HP:0100577
10 abnormality of the bladder 59 Very frequent (99-80%)
11 abnormality of the genital system 59 Very frequent (99-80%)
12 abnormality of the vagina 59 Occasional (29-5%)
13 functional abnormality of the bladder 59 Very frequent (99-80%)
14 abnormal vagina morphology 32 occasional (7.5%) HP:0000142

UMLS symptoms related to Interstitial Cystitis:


pain and other symptoms associated with female genital organs, mittelschmerz, unspecified symptom associated with female genital organs, other specified symptoms associated with female genital organs, female genital pain and other symptoms

MGI Mouse Phenotypes related to Interstitial Cystitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 ADRB2 BDNF HBEGF IL6 NGF P2RX3
2 cardiovascular system MP:0005385 10.02 ADRB2 CDH1 CXCR3 HBEGF IL6 NGF
3 growth/size/body region MP:0005378 10.02 ADRB2 BDNF CDH1 EGF HBEGF IL6
4 homeostasis/metabolism MP:0005376 10 ADRB2 BDNF CDH1 CXCR3 HBEGF IL6
5 integument MP:0010771 9.81 BDNF CDH1 EGF HBEGF IL6 NGF
6 normal MP:0002873 9.5 BDNF CDH1 CXCR3 EGF HBEGF NGF
7 renal/urinary system MP:0005367 9.1 CXCR3 IL6 TAC1 TRPV1 UMOD UPK3A

Drugs & Therapeutics for Interstitial Cystitis

Drugs for Interstitial Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
4
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
5
Belladonna Approved, Experimental Phase 4
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Cycloserine Approved Phase 4 68-41-7 6234 401
9
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
10
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
11
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3 56-12-2 119
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 1
14 abobotulinumtoxinA Phase 4,Phase 2,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Neuromuscular Agents Phase 4,Phase 2,Phase 1
19 Acetylcholine Release Inhibitors Phase 4,Phase 2,Phase 1
20 onabotulinumtoxinA Phase 4,Phase 2,Phase 1
21 Botulinum Toxins Phase 4,Phase 2,Phase 1
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
23 Anti-Arrhythmia Agents Phase 4,Phase 2,Not Applicable
24 Analgesics, Non-Narcotic Phase 4,Phase 3
25 Adrenergic alpha-Agonists Phase 4
26 Adrenergic Agonists Phase 4,Phase 3
27 Hypnotics and Sedatives Phase 4,Not Applicable
28 Adrenergic alpha-2 Receptor Agonists Phase 4
29 Analgesics Phase 4,Phase 3,Phase 2
30 Anti-Anxiety Agents Phase 4,Phase 3
31 Adrenergic Agents Phase 4,Phase 3
32 Analgesics, Opioid Phase 4,Phase 2
33 Oxytocics Phase 4
34 Ketorolac Tromethamine Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2
37 Cyclooxygenase Inhibitors Phase 4
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
39 Narcotics Phase 4,Phase 2
40 Opiate Alkaloids Phase 4
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2
42 Anti-Infective Agents, Urinary Phase 4
43 Antitubercular Agents Phase 4,Phase 3
44 Anti-Bacterial Agents Phase 4,Phase 3
45 Renal Agents Phase 4
46 Antimetabolites Phase 4
47 Antibiotics, Antitubercular Phase 4,Phase 3
48 Autonomic Agents Phase 4,Phase 3,Not Applicable
49 Anticoagulants Phase 4,Phase 2
50 Psychotropic Drugs Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
2 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
3 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
4 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Completed NCT02297100 Phase 4 Onabotulinumtoxin A
5 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
6 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
7 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
8 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
9 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
10 Interstitial Cystitis: Examination of the Central Autonomic Network Recruiting NCT03008382 Phase 4 Metoprolol Tartrate Oral Tablet;Placebo Oral Tablet
11 Chronic Pain Risk Associated With Menstrual Period Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
12 Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Terminated NCT00086684 Phase 4 Pentosan polysulfate sodium 100 mg;Placebo;Pentosan polysulfate sodium 100 mg
13 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
14 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
15 Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms Unknown status NCT00094874 Phase 3
16 Efficacy Study of Adalimumab to Treat Interstitial Cystitis Completed NCT01295814 Phase 3 Adalimumab
17 Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome Completed NCT01294878 Phase 3 omalizumab
18 URACYST® For the Treatment of GAG Deficient Interstitial Cystitis Completed NCT00150488 Phase 2, Phase 3
19 Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) Completed NCT00124306 Phase 3 Amitriptyline
20 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Completed NCT02497976 Phase 3 Placebo
21 A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Completed NCT02497287 Phase 3 Esketamine (Intranasal Spray);Duloxetine (Oral Antidepressant);Escitalopram (Oral Antidepressant);Sertraline (Oral Antidepressant);Venlafaxine Extended Release (XR) (Oral Antidepressant)
22 A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis Recruiting NCT02787083 Phase 3 Mirabegron;Placebo
23 Clinical Trial Comparing Two Bladder Instillations for IC/BPS Recruiting NCT03463915 Phase 3 Bladder instillation WITH triamcinolone acetonide;Bladder instillation WITHOUT triamcinolone acetonide
24 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Active, not recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
25 A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . Terminated NCT00451867 Phase 3 Mycophenolate Mofetil;Mycofenolate Mofetil (MMF);Placebo
26 Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions Unknown status NCT01437579 Phase 2
27 Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action Completed NCT01990898 Phase 2 Cyclosporine
28 Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis Completed NCT01479725 Phase 2
29 Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome Completed NCT00919113 Phase 2 2% sodium chondroitin sulfate;Placebo
30 Interstitial Cystitis Completed NCT00056251 Phase 2
31 An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis Completed NCT00739739 Phase 2 PD 0299685 at 15mg BID;PD 0299685 at 30mg BID;placebo for PD 0299685
32 Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment Completed NCT01969773 Phase 2 Botulinum toxin A;Normal saline instillation
33 Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis Completed NCT00295854 Phase 2 MN-001 BID;MN-001;Placebo
34 Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome Completed NCT01393223 Phase 2 LP-08 80mg;Normal saline;LP-08 20mg
35 A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Completed NCT00527917 Phase 2
36 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome Completed NCT02411110 Phase 2
37 Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Completed NCT02247557 Phase 2 Liposome encapsulated BoNT-A;BOTOX 200U in normal saline;Normal saline
38 An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis Completed NCT00601484 Phase 2 PF-04383119;Placebo
39 Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC Completed NCT00420550 Phase 2
40 A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) Completed NCT01613586 Phase 2 ASP3652;Placebo
41 Efficacy and Safety of AQX-1125 in IC/BPS Completed NCT01882543 Phase 2 AQX-1125;Placebo
42 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions Completed NCT02395042 Phase 2 LiRIS®;LiRIS Placebo
43 Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis Completed NCT00004316 Phase 1, Phase 2 capsaicin
44 Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients Completed NCT01997983 Phase 1, Phase 2
45 The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome Completed NCT01569438 Phase 2 Gefapixant;Sugar Pill
46 Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis Completed NCT00517868 Phase 2 URG101;Placebo
47 OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Completed NCT01197261 Phase 2 Oxycodone naloxone prolonged release tablets;Placebo tablets
48 Study of U101 for Bladder Pain and/or Urgency Completed NCT00256542 Phase 2 Alkalinized Lidocaine-Heparin
49 A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression Completed NCT01998958 Phase 2 Esketamine 14 mg;Esketamine 28 mg;Esketamine 56 mg;Esketamine 84 mg;Placebo
50 Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Recruiting NCT03076762 Phase 2 intravesical onabotulinumtoxinA injection

Search NIH Clinical Center for Interstitial Cystitis

Cochrane evidence based reviews: cystitis, interstitial

Genetic Tests for Interstitial Cystitis

Anatomical Context for Interstitial Cystitis

MalaCards organs/tissues related to Interstitial Cystitis:

41
Testes, Kidney, Prostate, Brain, Bone, Heart, Spinal Cord

Publications for Interstitial Cystitis

Articles related to Interstitial Cystitis:

(show top 50) (show all 1129)
# Title Authors Year
1
Validation of the Spanish version of the Bladder Pain/Interstitial Cystitis-Symptom Score (BPIC-SS) questionnaire. A useful tool for the diagnosis of bladder pain syndrome. ( 29650471 )
2018
2
Safety and Feasibility of Intravesical Instillation of Botulinum Toxin-A in Hydrogel-based Slow-release Delivery System in Patients With Interstitial Cystitis-Bladder Pain Syndrome: A Pilot Study. ( 29307733 )
2018
3
Urinary and psychological outcomes in women with interstitial cystitis/bladder pain syndrome following hyaluronic acid treatment. ( 29880165 )
2018
4
Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome. ( 29906407 )
2018
5
The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol. ( 29363792 )
2018
6
Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. ( 29372285 )
2018
7
Animal Model of Interstitial Cystitis/Bladder Pain Syndrome. ( 29385782 )
2018
8
Differences in Urodynamic Parameters According to the Presence of a Hunner Lesion in Women With Interstitial Cystitis/Bladder Pain Syndrome. ( 29385787 )
2018
9
Animal Modelling of Interstitial Cystitis/Bladder Pain Syndrome. ( 29385788 )
2018
10
Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion. ( 29955137 )
2018
11
Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. ( 29331031 )
2018
12
Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). ( 29341502 )
2018
13
Improving the utility of clinical phenotyping in interstitial cystitis/painful bladder syndrome: from UPOINT to INPUT. ( 29680002 )
2018
14
Endometriosis increased the risk of bladder pain syndrome/interstitial cystitis: A population-based study. ( 29318645 )
2018
15
Epstein-Barr Virus Presence as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. ( 29653163 )
2018
16
FDA Brudac 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for IC/BPS Research. ( 29452126 )
2018
17
An evaluation of the pharmacotherapy for interstitial cystitis. ( 29972328 )
2018
18
Management of interstitial cystitis/bladder pain syndrome. ( 29875041 )
2018
19
Repetitive transcranial magnetic stimulation for chronic neuropathic pain in patients with bladder pain syndrome/interstitial cystitis. ( 29797500 )
2018
20
Female Veterans With Diagnoses of Both Chronic Pelvic Pain and Overactive Bladder; How Do They Compare to Women Diagnosed With Interstitial Cystitis? ( 29746393 )
2018
21
Bladder pain syndrome/interstitial cystitis is associated with asthma: A case-control study. ( 29441652 )
2018
22
Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies? ( 29764932 )
2018
23
IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model. ( 29784508 )
2018
24
Inflammation and Tissue Remodeling in the Bladder and Urethra in Feline Interstitial Cystitis. ( 29706873 )
2018
25
Oncosuppressor protein p53 and cyclin-dependent kinase inhibitor p21 regulate interstitial cystitis associated gene expression. ( 29729649 )
2018
26
Prodrome and Non-prodrome Phenotypes of Bladder Pain Syndrome/Interstitial Cystitis. ( 29775697 )
2018
27
Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. ( 29879217 )
2018
28
Extent of Hunner lesions: The relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients. ( 29315774 )
2018
29
Will cesarean section increase the risk of interstitial cystitis/painful bladder syndrome? ( 29717503 )
2018
30
Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. ( 29392488 )
2018
31
Endoscopic Injection of Low Dose Triamcinolone: A Simple, Minimally Invasive, and Effective Therapy for Interstitial Cystitis With Hunner Lesions. ( 29782887 )
2018
32
A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome. ( 29363787 )
2018
33
A central role for toll-like 4 (TLR4) receptors in interstitial cystitis? ( 29949393 )
2018
34
Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model. ( 29984341 )
2018
35
Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia. ( 30010251 )
2018
36
Pathology and terminology of interstitial cystitis/bladder pain syndrome: A review. ( 30015351 )
2018
37
Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. ( 30022124 )
2018
38
Current best practice management of interstitial cystitis/bladder pain syndrome. ( 30034539 )
2018
39
Impact of intravesical hyaluronic acid treatment on bladder inflammation in interstitial cystitis rat model. ( 30044599 )
2018
40
Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study. ( 30050942 )
2018
41
A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. ( 30072210 )
2018
42
Comparison of outpatient reimbursement for interstitial cystitis/bladder pain syndrome and rheumatoid arthritis treatment in Taiwan: A nationwide population-based study. ( 30073771 )
2018
43
Bridging pharmacotherapy and minimally invasive surgery in interstitial cystitis/bladder pain syndrome treatment. ( 30074829 )
2018
44
Re: FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for Research: J. C. Nickel and R. Moldwin J Urol 2018;200:39-42. ( 30081020 )
2018
45
Painful Bladder Syndrome/Interstitial Cystitis Successful Treatment with Montelukast: A Case Report and Literature Review. ( 30155378 )
2018
46
Stratification of Patients With Interstitial Cystitis/Bladder Pain Syndrome According to the Anatomical Bladder Capacity. ( 30170094 )
2018
47
Comparison of urologic and non-urologic presentation in interstitial cystitis/bladder pain syndrome patients with and without Hunner lesions. ( 30187950 )
2018
48
The Effects of Neurokinin-1 Receptor Antagonist in an Experimental Autoimmune Cystitis Model Resembling Bladder Pain Syndrome/Interstitial Cystitis. ( 30196377 )
2018
49
Interstitial Cystitis: An Update on the Disease Process and Treatment. ( 30212267 )
2018
50
Symptomatic overlap in overactive bladder and interstitial cystitis/bladder pain syndrome: development of a new algorithm. ( 30253040 )
2018

Variations for Interstitial Cystitis

Expression for Interstitial Cystitis

Search GEO for disease gene expression data for Interstitial Cystitis.

Pathways for Interstitial Cystitis

Pathways related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 ADRB2 CDH1 CXCL8 CXCR3 EGF HBEGF
2
Show member pathways
13.35 ADRB2 CXCL8 CXCR3 KNG1 P2RX3 TAC1
3
Show member pathways
13.23 BDNF CXCL8 CXCR3 EGF IL6 NGF
4
Show member pathways
13.03 BDNF EGF HBEGF IL6 NGF P2RX3
5
Show member pathways
12.92 BDNF CDH1 CXCL8 CXCR3 EGF HBEGF
6
Show member pathways
12.87 BDNF EGF HBEGF IL6 NGF
7
Show member pathways
12.84 BDNF EGF HBEGF IL6 NGF
8
Show member pathways
12.52 BDNF EGF IL6 NGF
9
Show member pathways
12.13 BDNF CDH1 EGF IL6 NGF
10
Show member pathways
11.98 BDNF CXCL8 HBEGF IL6 NGF
11
Show member pathways
11.93 EGF HBEGF IL6
12 11.8 BDNF CXCL8 IL6
13
Show member pathways
11.65 BDNF CDH1 CXCL8 EGF IL6 NGF
14 11.57 BDNF EGF NGF
15 11.57 BDNF CXCL8 IL6 NGF TAC1
16 11.5 BDNF EGF IL6 NGF
17 11.47 CXCL8 HBEGF IL6
18 11.43 CXCL8 EGF IL6
19 10.88 CDH1 CXCL8 EGF HBEGF UPK3A
20 10.85 CXCL8 IL6
21 10.7 BDNF CDH1 CXCL8 EGF IL6 NGF
22 10.67 BDNF EGF

GO Terms for Interstitial Cystitis

Cellular components related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 ADRB2 CDH1 CXCR3 EGF HBEGF KNG1
2 extracellular space GO:0005615 9.56 BDNF CXCL8 EGF HBEGF IL6 KNG1
3 axon GO:0030424 9.46 BDNF NGF P2RX3 TAC1
4 extracellular region GO:0005576 9.32 BDNF CDH1 CXCL8 EGF HBEGF IL6

Biological processes related to Interstitial Cystitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.84 IL6 KNG1 NGF TRPV1
2 regulation of signaling receptor activity GO:0010469 9.65 BDNF CXCL8 HBEGF IL6 NGF
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 EGF HBEGF IL6
4 neurotrophin TRK receptor signaling pathway GO:0048011 9.57 BDNF NGF
5 response to pain GO:0048265 9.56 TAC1 TRPV1
6 cellular response to ATP GO:0071318 9.55 P2RX3 TRPV1
7 nerve development GO:0021675 9.52 BDNF NGF
8 activation of transmembrane receptor protein tyrosine kinase activity GO:0007171 9.51 ADRB2 EGF
9 nerve growth factor signaling pathway GO:0038180 9.49 BDNF NGF
10 positive regulation of acute inflammatory response GO:0002675 9.48 IL6 TAC1
11 behavioral response to pain GO:0048266 9.46 P2RX3 TRPV1
12 regulation of protein localization to cell surface GO:2000008 9.4 BDNF EGF
13 diet induced thermogenesis GO:0002024 9.37 ADRB2 TRPV1
14 positive regulation of collateral sprouting GO:0048672 9.32 BDNF NGF
15 positive regulation of cytosolic calcium ion concentration GO:0007204 9.26 CXCR3 KNG1 TAC1 TRPV1
16 urinary bladder smooth muscle contraction GO:0014832 9.16 P2RX3 TRPV1
17 inflammatory response GO:0006954 9.1 CXCL8 CXCR3 IL6 KNG1 TAC1 TRPV1

Molecular functions related to Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.02 BDNF EGF HBEGF IL6 NGF

Sources for Interstitial Cystitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....